The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.
 
Jacob Sands
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Gilead Sciences; Guardant Health; Lilly; Medtronic; PharmaMar; Sanofi
Research Funding - Amgen; Harpoon
Travel, Accommodations, Expenses - AstraZeneca
 
Sara M. Tolaney
Consulting or Advisory Role - AADi; ARC Therapeutics; Artios Biopharmaceuticals; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; CytomX Therapeutics; Daiichi Sankyo; eFFECTOR Therapeutics; Eisai; Genentech; Hengrui Pharmaceutical (USA); Immunomedics/Gilead; Incyte; Infinity Pharmaceuticals; Jazz Pharmaceuticals; Lilly; Menarini Group; Merck; Natera; Novartis; OncXerna Therapeutics; Pfizer; Reveal Genomics; Sanofi; Seagen; Sumitovant Biopharma; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Novartis (Inst); OncoPep (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Lilly; Sanofi
 
Naoto Tada Ueno
Stock and Other Ownership Interests - Pear Bio
Honoraria - Anheart Therapeutics; Bayer; Bristol-Myers Squibb/Celgene; Carna Biosciences; Chugai/Roche; CytoDyn; Daiichi Sankyo; Genomic Health; Kyowa Hakko Kirin; Kyowa Kirin International; Medscape; Medsir; Pfizer; Pfizer; Phoenix Molecular Designs; Sumitomo Dainippon Pharma Oncology; Sysmex
Consulting or Advisory Role - Anheart Therapeutics; Bayer; Bristol-Myers Squibb/Celgene; Carna Biosciences; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Phoenix Molecular Designs; Preferred Medicine; Sysmex
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; CytoDyn; Daiichi Sankyo; Duality Biologics; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Preferred Medicine; Puma Biotechnology; Sysmex
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Inspirna
Honoraria - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Ed Med Resources (OncInfo); Eisai; Geneos; Genzyme; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Lilly; Lynx Health; Master Clinician Alliance; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; Zymeworks
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Clinical Care Options; Daiichi Sankyo; Ed Med Resources (OncLive); Eisai; Geneos; Genzyme; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; H.C. Wainwright & Co.; HMP Education; Imedex; Imugene; Inspirna; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Physicians' Education Resource, LLC; Research to Practice; Seagen; Silverback Therapeutics; Zymeworks
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Inspirna (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Stand up to Cancer (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Yoichi Naito
Consulting or Advisory Role - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; FUJIFILM Toyama Chemistry; Gardant Pharmaceuticals; Hisamitsu Pharmaceutical; Lilly; MSD; Mundipharma; Novartis; Ono Yakuhin; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; AstraZeneca Japan; Boehringer Ingelheim; Chugai/Roche; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical; Takeda
 
Senthil Damodaran
Consulting or Advisory Role - AstraZeneca; Taiho Oncology
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); DualityBio (Inst); EMD Serono (Inst); Guardant Health (Inst); MediLink Therapeutics (Inst); Novartis (Inst); Sermonix Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst)
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Shanu Modi
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; DualityBio; Genentech; Gilead Sciences; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; DualityBio; Genentech; Gilead Sciences; GlaxoSmithKline; Lilly; Macrogenics; Puma Biotechnology; Seagen; Zymeworks
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); DualityBio (Inst); Nuvation Bio (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Peter C. Enzinger
Consulting or Advisory Role - ALX Oncology; Amgen; Arcus Biosciences; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Eisai; IDEAYA Biosciences; Legend Biotech; Legend Biotech; Lilly; Loxo; loxo; Merck; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Regeneron; Sanofi; SERVIER; Taiho Oncology; Taiho Pharmaceutical; Takeda; Takeda; Turning Point Therapeutics; Turning Point Therapeutics; Xencor; Xencor; Zymeworks
 
Avani Shah Mohapatra
Employment - Daiichi Sankyo
 
Yuka Iko
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Siwen He
Employment - Daiichi Sankyo
 
Keiko Nakajima
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)